Mixed bag? Biogen's aducanumab shows continued dose-correlation
This article was originally published in Scrip
Executive Summary
Biogen reported data from the 6mg/kg cohort of its PRIME trial of aducanumab at the Alzheimer's Association International Conference (AAIC) on 22 July that will likely leave investors itching for more clarity. The data continue to show dose correlation in efficacy, but safety issues persist at the mid-range dose as well.